CNBC's Meg Tirrell, has the latest details on the White House summit with medical researchers.» Read More
Philadelphia's transit agency has filed a lawsuit against Gilead Sciences challenging the "exorbitant pricing" of its hepatitis C drug Sovaldi.
As 2014's trading days dwindle, some traders are turning toward small cap stocks in hopes of boosting their portfolio returns.
Discovering and developing new treatments for diseases is notoriously expensive, but now it could be becoming slightly more financially rewarding.
Valeant Pharmaceuticals is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt and boost its stock price.
Celgene's partnering strategy, which has accelerated in recent years, is starting to bear fruit; many of the most-watched stocks out of ASH fall under its umbrella.
Three small-cap drug firms are consistently the best biotech performers following the start of the American Society of Hematology's annual meeting.
Doctors who used Genentech's expensive eye drug Lucentis were also among the highest-paid consultants for the company, reports the New York Times.
CNBC's Meg Tirrell reports on hottest new technologies from the annual meeting of the American Society of Hematology.
Drug giant Merck said it will buy Cubist and its slate of medicines administered in hospitals, many for bacterial infections, for about $9.5 billion.
The American Society of Hematology is holding a massive conference in San Francisco on Saturday. CNBC's Meg Tirrell tells why pharma and biotech investors are paying close attention.
Much of the influenza virus in the U.S. has mutated and this year's vaccine doesn't provide good protection against it, NBC News reports.
Biogen Idec said its experimental medicine for Alzheimer's disease showed promise, prompting it to move "aggressively" into the most advanced stage of studies.
Google-backed genetic testing service 23andMe is launching in the U.K., with the CEO pledging that data would not be shared with Google.
Using flawless English and an insider’s knowledge of Wall Street, the cybercriminals have gained access to the inboxes of top health care executives.
GSK will ax hundreds of U.S. jobs in its biggest market as the drugmaker starts implementing a major cost-saving program.
Pfizer's attempt to take over AstraZeneca through a $110 billion bid would have run aground on changes to U.S. tax laws, even if the companies had reached a deal.
An experimental Ebola vaccine made by GlaxoSmithKline caused no serious side effects, scientists reported on Wednesday.
Strongbody Apparel is selling activewear treated with technology from crab and shrimp shells to prevent odors and wrinkles.
Generic drug costs have risen so much that some drugs have surpassed their equivalents in other developed countries, the New York Times reports.
There are few new cancer drugs to treat kids, and not much research is being done.
Get the best of CNBC in your inbox